Genital Warts Market Report 2024

The genital warts market size has grown strongly in recent years. It will grow from $1.87 billion in 2023 to $1.97 billion in 2024 at a compound annual growth rate (CAGR) of 5.4%. The growth during the historic period can be attributed to several factors, a greater focus on patient-centered care, an increased emphasis on early detection and treatment, the rising availability of therapies designed for self-application, and a higher number of clinical trials addressing the recurrence of genital warts.

The genital warts market size is expected to see strong growth in the next few years. It will grow to $2.44 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The projected growth during the forecast period can be attributed to several factors, the adoption of telemedicine and digital health platforms for remote consultations and treatment monitoring, rising demand for effective and affordable STI treatments, the increasing popularity of loop electrosurgical excision procedures, higher demand for interferon alfa-n3 injections, and the growing availability of therapies. Key trends expected to shape this period include advancements in diagnostic technologies, a shift toward combination therapies, expanded use of telehealth and online consultations, the emergence of novel therapeutic targets, and market expansion into emerging regions.

The rising prevalence of sexually transmitted infections (STIs) is expected to drive growth in the genital warts market. STIs, transmitted primarily through sexual contact such as vaginal, anal, and oral sex, are caused by bacteria, viruses, or parasites. The increase in STI prevalence is attributed to higher sexual activity, insufficient use of protection, and limited access to education and healthcare. Genital warts, a common STI, are caused by specific strains of human papillomavirus (HPV) and spread through direct skin-to-skin contact during sexual activity. For example, the Joint United Nations Programme on HIV/AIDS, based in Switzerland, reported in October 2023 that HIV infections rose from 38.7 million in 2021 to 39 million in 2022, with 1.3 million new infections in 2022. This growing prevalence of STIs is fueling the expansion of the genital warts market.

Companies in the genital warts market are focusing on developing innovative treatment options, such as new dermatology drugs, to address the needs of patients with genital warts. Dermatology drugs are newly developed pharmaceuticals aimed at treating various skin conditions, including genital warts. For instance, in March 2023, Verrica Pharmaceuticals Inc., a US-based dermatology company, received New Chemical Entity (NCE) status from the FDA for its drug candidate YCANTH. YCANTH, which has completed phase 2 trials, is being developed to treat genital warts and will benefit from at least five years of protection from generic competition due to its NCE status.

In March 2021, Verrica Pharmaceuticals Inc. entered into a partnership with Torii Pharmaceutical Co. Ltd. to develop and commercialize Verrica's product candidates, including YCANTH, for treating molluscum contagiosum and warts in Japan. This collaboration aims to advance the development and market availability of genital wart treatments. Torii Pharmaceutical Co. Ltd., based in Japan, is working on developing YCANTH (VP-102) for external genital warts.

Major companies operating in the genital warts market are Merck & Co.Inc., AbbVie Inc, Sanofi S.A, Novartis AG, 3M Company, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc, Sun Pharmaceuticals, Perrigo Company plc, Glenmark Pharmaceutical Inc, Taro Pharmaceutical Industries Ltd, Serum Institute of India Pvt. Ltd., ANI Pharmaceuticals Inc, Ligand Pharmaceuticals Incorporated, Orgenesis Inc, Verrica Pharmaceuticals Inc, CryoConcepts LP, CryoIQ global AB, Cassiopea Inc, Aresus Pharma Inc.

North America was the largest region in the genital warts market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genital warts market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the genital warts market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Genital warts, also known as condylomata acuminata, are sexually transmitted infections caused by specific strains of the human papillomavirus (HPV). These warts typically manifest as small growths or clusters of bumps in or around the genital and anal areas. They can vary in size and shape, may be raised or flat, and often have a cauliflower-like appearance. Although generally painless, genital warts can lead to itching, discomfort, or bleeding during sexual intercourse.

The primary medications for treating genital warts include imiquimod, podophyllin, podofilox, and trichloroacetic acid. Imiquimod is a topical cream that works by stimulating the immune system to combat HPV-related warts. Treatment options also encompass chemical treatments, ablative treatments, preventive treatments, and other therapeutic approaches. These treatments are used by both females and males in various settings, such as hospitals, clinics, and home care environments.

The genital warts market research report is one of a series of new reports that provides genital warts market statistics, including genital warts industry global market size, regional shares, competitors with a genital warts market share, detailed genital warts market segments, market trends and opportunities, and any further data you may need to thrive in the genital warts industry. This genital warts market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genital warts market consists of revenues earned by entities by providing services such as medical consultations, diagnostic testing, treatment procedures, follow-up care, and patient education programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The genital warts market also includes sales of topical treatments, cryotherapy devices, surgical instruments, immune response modifiers, and antiviral medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.